Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics
Advanced Healthcare Materials,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 23, 2025
Abstract
Niclosamide,
initially
developed
as
an
anthelmintic,
has
recently
emerged
a
potential
antiviral,
showing
efficacy
against
diverse
viral
threats,
including
Mpox.
As
the
global
health
landscape
faces
recurrent
Mpox
outbreaks,
repurposing
niclosamide
through
advanced
material
strategies
offers
promising
therapeutic
avenues.
This
article
explores
antiviral
mechanisms
of
niclosamide,
focusing
on
how
innovative
nano‐hybrid
formulations
enhance
its
bioavailability
and
pharmacological
performance.
By
leveraging
nanohybridization,
niclosamide's
limitations—such
poor
solubility
bioavailability—are
addressed,
enabling
targeted
delivery
sustained
release.
Early
preclinical
studies
reveal
that
disrupts
replication
entry
processes,
suggesting
utility
option
poxvirus
infections.
Looking
forward,
further
in
vitro,
animal
models,
clinical
investigations
are
essential
to
optimize
application
dosing
for
With
continued
development
materials,
nanohybrid
could
become
critical
tool
managing
related
offering
accessible,
cost‐effective
outbreak
preparedness.
Language: Английский
Intentions of healthcare seeking and self-isolation for MPOX among men who have sex with men in China: a national cross-sectional study
Emerging Microbes & Infections,
Journal Year:
2024,
Volume and Issue:
13(1)
Published: May 7, 2024
Linking
identified
MPOX
cases
to
care
is
essential
for
control.
This
study
aims
investigate
the
intentions
of
healthcare
seeking
and
self-isolation
among
men
who
have
sex
with
(MSM)
in
China.
A
cross-sectional
online
survey
was
conducted
early
August
2023
Respondents
were
recruited
by
community-based
organizations
(CBOs),
collecting
information
on
demographics,
health
status,
behavioural
psychological
characteristics.
Univariate
multivariate
logistic
regression
analyses
performed
examine
predictors
seek
self-isolate
within
MSM
population.
total
7725
participants
recruited,
a
median
age
30
years.
92.21%
would
MPOX-like
symptoms,
but
only
52.50%
intended
if
diagnosed.
Intentions
lower
those
symptoms
past
3
months
(standardized
prevalence
ratio
(SPRs)
=
0.82,
95%
CI:
0.74-0.89)
willingness
reduced
diagnosed
(SPRs
0.65,
0.48-0.87).
Participants
free
sexually
transmitted
infections
(STIs)
aware
their
HIV
status
more
likely
than
STIs
or
unaware
status.
Regular
followers
perceiving
low
risk
infection
inclined
take
preventive
measures.
These
findings
highlight
need
targeted
prevention
strategies
high-risk
groups
importance
addressing
barriers
infectious
disease
response.
Language: Английский